<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/83570C3E-9613-45EB-BCBE-966B13BFAE4B"><gtr:id>83570C3E-9613-45EB-BCBE-966B13BFAE4B</gtr:id><gtr:name>University of Twente</gtr:name><gtr:address><gtr:line1>PO Box 217</gtr:line1><gtr:postCode>7500 AE</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Engineering Science</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/83570C3E-9613-45EB-BCBE-966B13BFAE4B"><gtr:id>83570C3E-9613-45EB-BCBE-966B13BFAE4B</gtr:id><gtr:name>University of Twente</gtr:name><gtr:address><gtr:line1>PO Box 217</gtr:line1><gtr:postCode>7500 AE</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A759FA25-0339-4639-B630-763937E256D4"><gtr:id>A759FA25-0339-4639-B630-763937E256D4</gtr:id><gtr:name>OrganOx Ltd</gtr:name><gtr:address><gtr:line1>The Magdalen Centre</gtr:line1><gtr:line2>Oxford Science Park</gtr:line2><gtr:line3>Robert Robinson Avenue</gtr:line3><gtr:postCode>OX4 4GA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/47459591-487B-41D6-A76D-7C1F753231C0"><gtr:id>47459591-487B-41D6-A76D-7C1F753231C0</gtr:id><gtr:name>Karl Storz GmbH &amp; Co. KG</gtr:name><gtr:address><gtr:line1>Mittlestrasse 8</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2855276D-55D7-4420-8A45-CC98A47A26FB"><gtr:id>2855276D-55D7-4420-8A45-CC98A47A26FB</gtr:id><gtr:name>Lein Applied Diagnostics Ltd</gtr:name><gtr:address><gtr:line1>Reading Enterprise Hub</gtr:line1><gtr:line2>The University of Reading</gtr:line2><gtr:line3>Earley Gate, Whiteknights Road</gtr:line3><gtr:postCode>RG6 6AU</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/27170BAD-BC94-44F1-9E3D-152745F86A7F"><gtr:id>27170BAD-BC94-44F1-9E3D-152745F86A7F</gtr:id><gtr:name>PsiOxus Therapeutics</gtr:name><gtr:address><gtr:line1>Cherwell Innovation Centre</gtr:line1><gtr:line4>Upper Heyford</gtr:line4><gtr:postCode>OX25 5HD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/88051761-6C81-4292-ACAF-D3AD0C610862"><gtr:id>88051761-6C81-4292-ACAF-D3AD0C610862</gtr:id><gtr:name>MedImmune Ltd</gtr:name><gtr:address><gtr:line1>Milstein Building</gtr:line1><gtr:line2>Granta Park</gtr:line2><gtr:line3>Sir Aaron Klug Building</gtr:line3><gtr:postCode>CB21 6GH</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/8A6AC24C-1A8A-4182-A443-95F24864DB56"><gtr:id>8A6AC24C-1A8A-4182-A443-95F24864DB56</gtr:id><gtr:name>Pfizer Global R and D</gtr:name><gtr:address><gtr:line1>Pfizer Global R and D</gtr:line1><gtr:line2>IPC475</gtr:line2><gtr:line3>Ramsgate Road</gtr:line3><gtr:line4>Sandwich</gtr:line4><gtr:line5>Kent</gtr:line5><gtr:postCode>CT13 9NJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C864B252-8646-4B9A-B1EF-B239DF840056"><gtr:id>C864B252-8646-4B9A-B1EF-B239DF840056</gtr:id><gtr:name>Oxford Instruments plc</gtr:name><gtr:address><gtr:line1>Tubney Woods</gtr:line1><gtr:line4>Abingdon</gtr:line4><gtr:line5>Oxfordshire</gtr:line5><gtr:postCode>OX13 5QX</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/CDFBE397-4163-4AA2-AEF7-437B248FFE89"><gtr:id>CDFBE397-4163-4AA2-AEF7-437B248FFE89</gtr:id><gtr:name>Cell Therapy</gtr:name><gtr:address><gtr:line1>Cardiff Gate Business Park</gtr:line1><gtr:line2>Malthouse Avenue</gtr:line2><gtr:line3>Pontprennau</gtr:line3><gtr:postCode>CF28 8RU</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B47667E4-7DC4-406C-86FF-4C31D20CDD50"><gtr:id>B47667E4-7DC4-406C-86FF-4C31D20CDD50</gtr:id><gtr:name>Verasonics Inc</gtr:name><gtr:address><gtr:line1>22222 NE 62nd Place</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/BE060C1C-7FDA-4E37-AB7D-73E0E67C6492"><gtr:id>BE060C1C-7FDA-4E37-AB7D-73E0E67C6492</gtr:id><gtr:firstName>Constantin</gtr:firstName><gtr:surname>Coussios</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2D77FDDC-6DFB-46B2-9FE8-7339D6EF7DB1"><gtr:id>2D77FDDC-6DFB-46B2-9FE8-7339D6EF7DB1</gtr:id><gtr:firstName>Katherine</gtr:firstName><gtr:otherNames>Anne</gtr:otherNames><gtr:surname>Vallis</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E8E4827B-90B1-480B-9B9A-218761FA0D88"><gtr:id>E8E4827B-90B1-480B-9B9A-218761FA0D88</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:otherNames>Crispin</gtr:otherNames><gtr:surname>Carlisle</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3E5976A0-A73A-48DA-8DFD-A02C982BDEFA"><gtr:id>3E5976A0-A73A-48DA-8DFD-A02C982BDEFA</gtr:id><gtr:firstName>Nicola</gtr:firstName><gtr:otherNames>Ruth</gtr:otherNames><gtr:surname>Sibson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/4A92977E-E8DA-4816-8D30-9175EA0FA66D"><gtr:id>4A92977E-E8DA-4816-8D30-9175EA0FA66D</gtr:id><gtr:firstName>Leonard</gtr:firstName><gtr:surname>Seymour</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/60C77415-2DC0-4359-920E-6BEAA3C15CAB"><gtr:id>60C77415-2DC0-4359-920E-6BEAA3C15CAB</gtr:id><gtr:firstName>Terence</gtr:firstName><gtr:surname>Rabbitts</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9053FA52-702E-45E3-821C-AB8EF1A8B73D"><gtr:id>9053FA52-702E-45E3-821C-AB8EF1A8B73D</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:surname>Moyle</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/64BAA93D-4F9F-4C74-9A2C-D0A76D74E3B3"><gtr:id>64BAA93D-4F9F-4C74-9A2C-D0A76D74E3B3</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Friend</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/114344EB-F4C9-432D-93A1-69A1117BF4E9"><gtr:id>114344EB-F4C9-432D-93A1-69A1117BF4E9</gtr:id><gtr:firstName>Eleanor</gtr:firstName><gtr:surname>Stride</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/CC772E5B-B044-48EE-9357-F5716319BC8B"><gtr:id>CC772E5B-B044-48EE-9357-F5716319BC8B</gtr:id><gtr:firstName>Robin</gtr:firstName><gtr:otherNames>Olav</gtr:otherNames><gtr:surname>Cleveland</gtr:surname><gtr:orcidId>0000-0002-1797-4704</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=EP%2FL024012%2F1"><gtr:id>6CD133AA-801F-4644-A6CB-CC1C49A5E344</gtr:id><gtr:title>OxCD3: Oxford Centre for Drug Delivery Devices</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/L024012/1</gtr:grantReference><gtr:abstractText>The greatest challenge in oncological drug delivery is achieving successful penetration and distribution of the therapeutic agent throughout the tumour: billions of pounds have been spent to date in deploying biochemical approaches in an attempt to solve what is essentially an engineering problem, namely the transport of therapeutics from the blood stream to reach every cancer cell. 

OxCD3 will seek to transform both clinical and industry practice in drug delivery by demonstrating the value and feasibility of engineering approaches, involving a combination of stimulus-responsive nanocarriers and medical devices already in clinical use, for improved tumour uptake and therapeutic outcome. The Programme Grant will enable the creation of a sustainable, world-unique multi-disciplinary environment for combinational engineering of biology, chemistry and medical devices to improve drug delivery under a single roof. It is also expected to create a unique training environment for the next generation of young scientists working on combination therapies and biomedical nanotechnology, by providing direct exposure to regulatory and manufacturing issues encountered when translating laboratory research into production and clinical practice. 

A unique feature of the Centre is the capability to design both devices and drug delivery vehicles under a single roof. In the first 5 years, under EPSRC funding, up to 3 carefully selected &amp;quot;Device+Drug&amp;quot; exemplars will be manufactured to GMP, ready for Phase I clinical trials, to provide compelling evidence of feasibility to industrial partners and clinicians; in the next 5 years, a private-public partnership will be built to complete clinical trials of these exemplars using therapeutics of strategic significance to the pharmaceutical industry; beyond 10 years, full industrial sponsorship of the OXCD3 is anticipated, which will focus on addressing next-generation challenges in drug delivery (beyond cancer) in partnership with industry and clinicians. The transformative aim over 50 years is to position the UK as the world leader for multi-disciplinary drug delivery development, complementing its existing position as a drug discovery leader, from design to manufacture and clinical trials.</gtr:abstractText><gtr:potentialImpactText>The proposed programme grant spans two of EPSRC's core strategic areas, &amp;quot;Healthcare Technologies&amp;quot; and &amp;quot;Manufacturing the Future&amp;quot; and will be key in providing the UK with a world-leading position in the exploding fields of targeted drug delivery and nanotechnology biomanufacturing. In addition to academic excellence in addressing the greatest challenge in oncological drug delivery (achieving tumour penetration), its aim is to provide the underlying science and manufacturing know-how that will enable successful delivery of existing and future anti-cancer agents, transforming both UK healthcare and UK industry. 

True impact in biomedical engineering and drug delivery is achieved in one of three, often interlinked ways: translation from bench to bedside through clinical trials and demonstration of therapeutic efficacy; dissemination of transformative science and techniques through high-impact peer-reviewed publications for uptake by the academic and industrial communities; and commercialization of new advances, either through licensing to existing manufacturers or through the formation of new spin-out companies. 
The impact of major advances in drug delivery has historically been limited by three factors: 
(i) Scale-up: most innovative drug carrier manufacturing techniques developed in the laboratory are poorly suited to large-scale manufacturing, and often overlook the constraints of manufacturing to GMP as needed for clinical trials, thus requiring major and costly redevelopment before clinical trials and uptake by industry.
The OXCD3 difference: Involve the Clinical Biomanufacturing Facility from day one, so that laboratory techniques are selected from an early stage to be compatible with GMP scale-up. 
(ii) Non-anticipation of regulatory hurdles, particularly for complex combinational products: the choice of drug vehicle materials and of the type of excitation required for device-triggered release will greatly affect the cost and complexity of experimentation and biocompatibility studies required for regulatory approval to enter the clinic. 
The OXCD3 difference: Involve clinicians and a qualified pharmacist (QP) with direct experience of managing drug, device and combinational trials from day one, 
(iii) Excessively long timescale to first-in-man trials: 
The OXCD3 difference: Deliver not only transformative science but also three exemplars already manufactured to GMP ready for a clinical trial by the end of the funding period.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-07-22</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2014-07-23</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>6384336</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Twente</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>Physics of Fluids</gtr:department><gtr:description>High-speed imaging of ultrasound-enhanced drug delivery and associated mechnanisms</gtr:description><gtr:id>25166D2E-F019-4291-88C2-EB57FEC080F1</gtr:id><gtr:impact>In vitro methods to study bubble-cell interactions: Fundamentals and therapeutic applications. G Lajoinie, I De Cock, CC Coussios, I Lentacker, S Le Gac, E Stride, M Versluis Biomicrofluidics 10 (1), 011501 (2016)</gtr:impact><gtr:partnerContribution>Access to a world-unique ultra-high-speed camera (Brandaris) and access for up 10 weeks to an expert researcher to setup and conduct the experiments.</gtr:partnerContribution><gtr:piContribution>We have designed, manufactured and supplied novel vehicles for ultrasound-mediated drug delivery, expertise in real-time cavitation detection, and a member of staff for up to 10 weeks to help conduct experiments in Twente.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Research and Development AstraZeneca</gtr:department><gtr:description>Delivery of liposomal mRNA</gtr:description><gtr:id>19CC000E-7FEA-4AE5-B619-AA840B7A722B</gtr:id><gtr:impact>There are no published outputs yet.</gtr:impact><gtr:partnerContribution>We have been provided with a proprietary mRNA liposomal formulation and expertise on how to quantify mRNA delivery.</gtr:partnerContribution><gtr:piContribution>We have identified novel methods of delivering liposomal mRNA to cells using shock waves and ultrasound</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>LLR</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>A56D429A-D7C9-4A6E-AF34-045DDA868BA6</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Pioneer Award</gtr:description><gtr:end>2018-06-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>E5975D25-8613-4180-B140-3CA7E10A14C9</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2345550</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Senior Investigator Award</gtr:department><gtr:description>Wellcome Trust SI Award</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>99BACCB4-2E71-41F6-A2FF-65B94DF9DA19</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3825714</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Seeding Drug Development Award</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>B8FFA2D4-63A3-4B5B-AFB3-30647908C10C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>180000</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pancreatic Cancer Research Fund</gtr:description><gtr:end>2019-06-02</gtr:end><gtr:fundingOrg>Pancreatic Cancer Action (PCA)</gtr:fundingOrg><gtr:id>1BFB4844-102C-47B0-9909-F3122FE0B3FC</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2223000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Chromosomal translocation genes and their protein interactions in cancer</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>25ED9B09-07E6-4F4F-B04C-A25126E2E02B</gtr:id><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>The Oxford Centre for Drug Delivery Devices (OxCD3) launched on the 23rd July 2014 to address one of the greatest challenges in oncology: achieving successful penetration and distribution of the therapeutic agent throughout the tumour. 

The Centre's research spans 4 work packages (WPs), each led by at least one physical and one medical investigator, and resourced with two post-doctoral fellows and 2-3 doctoral (DPhil) students. 
o WP1 (Coussios, Seymour, Carlisle) exploits cavitating nanoparticles for ultrasound-enhanced delivery of biologics.
o WP2 (Carlisle, Vallis) develops liposomal encapsulation technologies for ultrasound-enhanced delivery of radiopharmaceuticals. 
o WP3 (Cleveland, Rabbitts) investigates the use of shock waves for delivery across the cell membrane. 
o WP4 (Stride, Sibson) is concerned with combining magnetic and ultrasound approaches for brain theranostics.</gtr:description><gtr:exploitationPathways>Active collaborations under CDAs and MTAs with pharma partners (GSK, Pfizer, AstraZeneca) to identify how to take these advances into the clinic over the next 3 years</gtr:exploitationPathways><gtr:id>A150D759-D186-439D-A29C-74810F9FD313</gtr:id><gtr:sectors><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://www.drugdelivery.org</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Invitation to discuss Secretary of Business, Energy and Industry Strategy how government can support growth of biomedical engineering businesses</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EA8D9290-5927-457B-87CA-6A7CA2D10DEF</gtr:id><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>www.oxsonics.com</gtr:companyName><gtr:description>Therapeutic ultrasound technologies for minimally invasive surgery and drug delivery</gtr:description><gtr:id>EDB6E405-5B5D-4099-A9D1-92A3D14CF34F</gtr:id><gtr:impact>Received a TSB Biocatalyst award for &amp;pound;2.1m, supplementing VC funding of &amp;pound;2.7m.</gtr:impact><gtr:url>http://www.oxsonics.com</gtr:url><gtr:yearCompanyFormed>2014</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B0826F20-9A17-452A-AD7D-093B53270727"><gtr:id>B0826F20-9A17-452A-AD7D-093B53270727</gtr:id><gtr:title>The Application of Clinical Lithotripter Shock Waves to RNA Nucleotide Delivery to Cells.</gtr:title><gtr:parentPublicationTitle>Ultrasound in medicine &amp; biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0df6a9c573b48a4a17d29aea63d8f80b"><gtr:id>0df6a9c573b48a4a17d29aea63d8f80b</gtr:id><gtr:otherNames>Nwokeoha S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0301-5629</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/71427C1E-A8B1-4ACA-A21D-47850DFBB147"><gtr:id>71427C1E-A8B1-4ACA-A21D-47850DFBB147</gtr:id><gtr:title>Ultrahigh-Speed Dynamics of Micrometer-Scale Inertial Cavitation from Nanoparticles</gtr:title><gtr:parentPublicationTitle>Physical Review Applied</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d87aeb390927962b3f17b56a87bf8df2"><gtr:id>d87aeb390927962b3f17b56a87bf8df2</gtr:id><gtr:otherNames>Kwan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D90DFA14-C315-4FCC-800E-1C2536743766"><gtr:id>D90DFA14-C315-4FCC-800E-1C2536743766</gtr:id><gtr:title>Ultrasound-induced inertial cavitation from gas-stabilizing nanoparticles.</gtr:title><gtr:parentPublicationTitle>Physical review. E, Statistical, nonlinear, and soft matter physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f323ffdaa02cac7311cd2c46d9173c8b"><gtr:id>f323ffdaa02cac7311cd2c46d9173c8b</gtr:id><gtr:otherNames>Kwan JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1539-3755</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9BDD77C4-5B23-4FC3-8CAE-1A926A51130B"><gtr:id>9BDD77C4-5B23-4FC3-8CAE-1A926A51130B</gtr:id><gtr:title>Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3bd03721ac28e38ea9ce5846991fc7c9"><gtr:id>3bd03721ac28e38ea9ce5846991fc7c9</gtr:id><gtr:otherNames>Myers R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/477DF148-ADFC-4582-A6E4-D9C6C8AF467B"><gtr:id>477DF148-ADFC-4582-A6E4-D9C6C8AF467B</gtr:id><gtr:title>Passive acoustic mapping of magnetic microbubbles for cavitation enhancement and localization.</gtr:title><gtr:parentPublicationTitle>Physics in medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/562f0f320baf32db7345b1b776887073"><gtr:id>562f0f320baf32db7345b1b776887073</gtr:id><gtr:otherNames>Crake C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0031-9155</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5FBA51DB-D238-4768-9D47-E9B0C8D061BE"><gtr:id>5FBA51DB-D238-4768-9D47-E9B0C8D061BE</gtr:id><gtr:title>Exploitation of sub-micron cavitation nuclei to enhance ultrasound-mediated transdermal transport and penetration of vaccines.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/be318db9ee8902432be0328f20a5ef45"><gtr:id>be318db9ee8902432be0328f20a5ef45</gtr:id><gtr:otherNames>Bhatnagar S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/10F5DBAE-4482-49C0-B13B-8BD1BBC9E1C7"><gtr:id>10F5DBAE-4482-49C0-B13B-8BD1BBC9E1C7</gtr:id><gtr:title>Ultrasound-Propelled Nanocups for Drug Delivery.</gtr:title><gtr:parentPublicationTitle>Small (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f323ffdaa02cac7311cd2c46d9173c8b"><gtr:id>f323ffdaa02cac7311cd2c46d9173c8b</gtr:id><gtr:otherNames>Kwan JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1613-6810</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/70E8AF51-A8B6-4BCE-AA0E-B82175AB4126"><gtr:id>70E8AF51-A8B6-4BCE-AA0E-B82175AB4126</gtr:id><gtr:title>Enhancement and Passive Acoustic Mapping of Cavitation from Fluorescently Tagged Magnetic Resonance-Visible Magnetic Microbubbles In&amp;nbsp;Vivo.</gtr:title><gtr:parentPublicationTitle>Ultrasound in medicine &amp; biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/562f0f320baf32db7345b1b776887073"><gtr:id>562f0f320baf32db7345b1b776887073</gtr:id><gtr:otherNames>Crake C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0301-5629</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AE12AB95-AE1E-4E11-BB9D-EE8009374292"><gtr:id>AE12AB95-AE1E-4E11-BB9D-EE8009374292</gtr:id><gtr:title>Nanoparticle-Loaded Protein-Polymer Nanodroplets for Improved Stability and Conversion Efficiency in Ultrasound Imaging and Drug Delivery.</gtr:title><gtr:parentPublicationTitle>Advanced materials (Deerfield Beach, Fla.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/21f6a74a058e015d4e6791267279c0be"><gtr:id>21f6a74a058e015d4e6791267279c0be</gtr:id><gtr:otherNames>Lee JY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0935-9648</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1BF0D573-7074-49CC-A635-2DB991DC88E2"><gtr:id>1BF0D573-7074-49CC-A635-2DB991DC88E2</gtr:id><gtr:title>Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5269617b5027c3fb34c0629d70e09617"><gtr:id>5269617b5027c3fb34c0629d70e09617</gtr:id><gtr:otherNames>Tedcastle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7FF53F47-7EED-4AFF-A386-FC77A9F94AD2"><gtr:id>7FF53F47-7EED-4AFF-A386-FC77A9F94AD2</gtr:id><gtr:title>Increasing the density of nanomedicines improves their ultrasound-mediated delivery to tumours.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f1bbc779cb6801f86e5e57b8412b6976"><gtr:id>f1bbc779cb6801f86e5e57b8412b6976</gtr:id><gtr:otherNames>Mo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2C3360C5-093B-4C60-8B18-C9904A8D028F"><gtr:id>2C3360C5-093B-4C60-8B18-C9904A8D028F</gtr:id><gtr:title>Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer.</gtr:title><gtr:parentPublicationTitle>Expert opinion on drug delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/34e93bf4583cf44586e60f8e80da48c5"><gtr:id>34e93bf4583cf44586e60f8e80da48c5</gtr:id><gtr:otherNames>Grundy M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1742-5247</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8E825BE6-E890-47F3-9607-4E6DDCCA9412"><gtr:id>8E825BE6-E890-47F3-9607-4E6DDCCA9412</gtr:id><gtr:title>The effect of particle density on ultrasound-mediated transport of nanoparticles.</gtr:title><gtr:parentPublicationTitle>Physics in medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5da534a3ce6d9a0e7cfa466b140dc05f"><gtr:id>5da534a3ce6d9a0e7cfa466b140dc05f</gtr:id><gtr:otherNames>Lea-Banks H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0031-9155</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/858F8C37-818F-46F5-BD49-9E78DE9D2604"><gtr:id>858F8C37-818F-46F5-BD49-9E78DE9D2604</gtr:id><gtr:title>Exploitation of acoustic cavitation-induced microstreaming to enhance molecular transport.</gtr:title><gtr:parentPublicationTitle>Journal of pharmaceutical sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/be318db9ee8902432be0328f20a5ef45"><gtr:id>be318db9ee8902432be0328f20a5ef45</gtr:id><gtr:otherNames>Bhatnagar S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3549</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/L024012/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>